| Targeting PLHIV (%) | Targeting household contacts (%) | Total (%) |
---|---|---|---|
Reduction in annual incidence rate attributable to preventive therapy (2030 relative to 2015), under the improved cascade comparator | |||
 Bangladesh | 0.09 [0.05–0.14] | 4.38 [3.71–4.49] | 4.45 [3.79–5.60] |
 Bhutan | 0.10 [0.03–0.39] | 3.17 [2.57–3.95] | 3.25 [2.66–4.25] |
 DPR Korea | 0.09 [0.04–0.17] | 8.69[−2.07–14.81] | 8.79[−2.01–14.89] |
 India | 1.79 [1.14–2.91] | 4.53 [3.56–5.79] | 6.44 [5.08–8.33] |
 Indonesia | 1.53 [0.85–2.99] | 6.35 [5.50–7.99] | 7.81 [6.52–10.05] |
 Maldives | 0.03 [0.025–0.049] | 1.94 [1.43–2.86] | 1.97 [1.45–2.90] |
 Myanmar | 4.39 [2.70–7.69] | 7.96 [6.04–15.50] | 12.41 [9.02–23.00] |
 Nepal | 0.62 [0.44–0.94] | 4.62 [3.60–6.96] | 5.22 [4.12–7.78] |
 Sri Lanka | 0.20 [0.13–0.27] | 1.95 [1.49–2.65] | 2.15 [1.68–2.83] |
 Thailand | 5.69 [3.84–9.23] | 3.40 [2.50–5.62] | 9.06 [6.47–15.52] |
 Timor Leste | 1.06 [0.44–2.64] | 21.29 [12.18–38.06] | 22.39 [12.56–40.23] |
 SEAR | 1.81 [1.30–2.38] | 5.14 [4.38–6.14] | 6.93 [5.81–8.51] |
Reduction in annual TB mortality attributable to preventive therapy (2030 relative to 2015), under the improved cascade comparator | |||
 Bangladesh | 0.03 [0.01–0.10] | 1.67 [0.56–4.12] | 1.70 [0.57–4.21] |
 Bhutan | 0.05 [0.008–0.28] | 1.57 [0.43–4.49] | 1.67 [0.43–4.63] |
 DPR Korea | 0.05 [0.02–0.14] | 4.74[−1.13–14.81] | 4.80[− 1.08–14.94] |
 India | 1.05 [0.58–1.88] | 2.62 [1.59–4.29] | 3.59 [2.48–6.07] |
 Indonesia | 0.61 [0.35–1.15] | 2.57 [1.88–3.60] | 3.19 [2.40–4.60] |
 Maldives | 0.001 [0.0007–0.0013] | 0.07 [0.06–0.09] | 0.07 [0.06–0.09] |
 Myanmar | 1.98 [0.93–3.79] | 3.97 [1.76–7.67] | 6.02 [2.81–11.26] |
 Nepal | 0.53 [0.15–1.54] | 4.18 [1.02–11.47] | 4.71 [1.17–13.02] |
 Sri Lanka | 0.09 [0.04–0.25] | 0.97 [0.34–2.13] | 1.06 [0.38–2.29] |
 Thailand | 1.92 [0.78–5.12] | 1.15 [0.52–3.36] | 3.03 [1.23–7.89] |
 Timor Leste | 0.39 [0.10–1.33] | 9.00 [2.66–29.17] | 9.47 [2.75–30.10] |
 SEAR | 0.94 [0.58–1.45] | 2.60 [1.96–3.73] | 3.52 [2.72–5.08] |